5. Progressive supranuclear palsy
82 clinical trials,   107 drugs   (DrugBank: 36 drugs),   60 drug target genes,   90 drug target pathways

Searched query = "Progressive supranuclear palsy", "PSP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03545789
(ClinicalTrials.gov)
March 12, 201815/3/2018Phase 1 Test-retest Evaluation of [18F]MNI-958 PETPhase 1 Test-retest Evaluation of [18F]MNI-958 PET as an Imaging Marker for Tau Protein in the Brain of Patients With Alzheimer's Disease and Probable PSP as Compared to Healthy VolunteersHealthy Volunteers;Alzheimer Disease;Progressive Supranuclear PalsyDrug: [18F]MNI-958InvicroNULLCompleted18 Years55 YearsAll16Phase 1United States
2NCT03058965
(ClinicalTrials.gov)
November 29, 201612/1/2017Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the BrainPhase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Probable Alzheimer's Disease or Progressive Supranuclear Palsy Compared With Healthy VolunteersAlzheimer Disease;Healthy Volunteers;Progressive Supranuclear PalsyDrug: [18F]MNI-958;Drug: [18F]Florbetapir;Drug: DaTscanMolecular NeuroImagingNULLCompleted50 Years90 YearsAll12Early Phase 1United States